Benzinga | May 25, 2021 09:05AM EDT

Moleculin Biotech Receives Clearance To Initiate Phase 1b/2 Trial Of Annamycin

On May 25, 2021, Moleculin Biotech, Inc. (the "Company"), issued a press release announcing it has received clearance to initiate its Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.